Pafolacianine Production Cost Reports

The report provides detailed analysis essential for establishing a pafolacianine production plant. It encompasses all critical aspects necessary for pafolacianine production, including the cost of pafolacianine production, pafolacianine plant cost, pafolacianine production costs, and the overall pafolacianine production plant cost. Additionally, the study covers specific expenditures associated with setting up and operating a pafolacianine production plant. These encompass production processes, raw material requirements, utility requirements, infrastructure needs, machinery and technology requirements, manpower requirements, packaging requirements, transportation requirements, and more.

Pafolacianine Market Analysis: Demand and Supply Analysis, and Sourcing

Pafolacianine is a fluorescent imaging agent used during cancer surgery to light up folate receptor-positive tumors under near-infrared (NIR) imaging. Structurally it is a folic acid conjugate of the heptamethine cyanine dye S0456, joined through a tyrosinate linker. On Target Laboratories developed it as OTL38 and sells it as Cytalux, which the FDA cleared first for ovarian cancer and then for lung cancer surgery, with prostate cancer and other indications in trials. Surgeons give it intravenously as a sterile aqueous injection before the operation, and the paired NIR imaging system is regulated separately as a medical device.

Buyers are hospital and academic surgical centers that already run a paired NIR imaging camera. By volume, Cytalux is a niche agent, tied directly to the number of surgical cases that qualify for folate-receptor-guided resection, and On Target Laboratories runs the commercial supply through qualified CDMO partners with no generic alternative today. Reference-standard material is sourced in milligram quantities from catalog suppliers such as Selleckchem, MedKoo, and BOC Sciences. Anyone modeling demand and supply has to weigh the narrow case volume, folate-receptor expression in the target tumors, the installed base of paired imaging systems, and the pace of new-indication approvals. On receipt, API buyers verify assay by HPLC, related pterin and dye impurities, residual solvents, endotoxin, and fluorescence spectra.

Summary of the Product, Grades, and Uses

Pafolacianine sodium has the molecular formula C61H63N9Na4O17S4 and a molar mass of 1,414.42 g/mol as the tetrasodium salt, combining a folate ligand, a tyrosine spacer, and the S0456 cyanine dye. It ships as a dark green sterile solution in 5 mg per 3 mL vials, with absorption around 776 nm and emission around 793 nm, close to indocyanine green. The compound is soluble in water and saline and stays stable at 2 to 8 °C under light protection.

Pafolacianine is supplied in two grades. Injectable grade meets FDA specifications and ships internally at On Target Laboratories for Cytalux fill-finish, while reference-standard grade sells in milligram lots to research labs.

Ovarian cancer surgery is the original indication under the Cytalux brand. The patient receives an IV dose before surgery, and the surgical team uses a paired NIR camera to visualize folate-receptor-positive tissue in the peritoneal cavity; a phase 3 study reported that pafolacianine plus NIR imaging found extra tumor tissue in about 33% of patients, tissue not seen under white light or by palpation. Lung cancer surgery followed as the second indication, for known or suspected lung cancer. Prostate, head-and-neck, and other folate-receptor tumors are in earlier trials, and the head-and-neck data has been mixed. Reference-standard use adds a small share of demand at low tonnage but firmer pricing.

Main End-Uses of Pafolacianine

Pafolacianine demand today splits across a few surgical settings, and ovarian cancer surgery is the largest current end-use, taking most of the Cytalux vial volume. The buyers are academic cancer centers, comprehensive cancer hospitals, and surgical oncology programs that run a paired NIR imaging system. Because the dose is weight-based, each surgical case uses only a small quantity of API. Buyer checks cover vial integrity, cold-chain handling, lot-to-lot fluorescence consistency, and related-substance limits.

Lung cancer surgery is the second outlet, added after the second FDA indication. Here pafolacianine helps surgeons detect small folate-receptor-positive nodules during video-assisted or robotic thoracoscopic surgery, and its volume tracks how quickly thoracic programs qualify NIR imaging kits from Stryker, Olympus, and other paired-device suppliers. Hospitals check the same specifications used for ovarian lots.

Investigational work accounts for the rest of demand. On Target Laboratories is running trials in prostate cancer, endometrial cancer, head-and-neck squamous cell carcinoma, and other folate-receptor-positive tumors. Reference-standard suppliers such as Selleckchem, MedKoo, and BOC Sciences supply milligram lots for cyanine-dye conjugation research. Quantities are small, though the per-gram price sits several times above bulk supply.

Pafolacianine Market Risks

Pafolacianine faces a distinct set of commercial risks because it is a niche, single-source imaging agent. On Target Laboratories is effectively the sole commercial producer, so supply sits in very few hands and any disruption at its CDMO partners could halt hospital supply within weeks. The addressable patient base is narrow, since Cytalux only helps in folate-receptor-positive tumors and no companion diagnostic is routinely run before surgery. Payer coverage also varies widely across US commercial insurance and Medicare, and because reimbursement is bundled with the surgical episode rather than paid as a separate drug charge, per-vial pricing is under real pressure. Competition from other targeted intraoperative imaging agents, such as HER2- and PSMA-directed cyanine conjugates, is building, and a negative primary endpoint in head-and-neck surgical trials has trimmed the addressable indication list.

Pafolacianine manufacturing carries its own risks because the final conjugation step relies on nucleophilic meso-chloro displacement on the S0456 dye by a phenoxy nucleophile, and any drift in reaction conditions produces unwanted enamine byproducts that cut yield and purity. The tyrosinate linker was chosen precisely because the earlier glutamate linker gave an unstable enamine. Cyanine-dye synthesis at the S0456 step is itself complex and has few qualified suppliers, and fluorescence quantum yield is sensitive to residual impurities. Endotoxin control is demanding at the small batch sizes typical here. Most rejected batches trace back to related-substance HPLC failures and fluorescence drift.

Pafolacianine Production Process and Main Cost Drivers

The pafolacianine production process runs the full value chain, from pterin and dye intermediate receipt through folic acid tyrosinate coupling, S0456 dye conjugation, purification, ultrafiltration, sterile filtration, and aseptic fill-finish.

• By Meso-Chloro Displacement of S0456 by a Folate-Tyrosinate Phenoxy Nucleophile: The main inputs are trifluoroacetylpteroic acid, protected tyrosinate linker, S0456 heptamethine cyanine dye, coupling reagents, DMF & DCM solvents, deprotection reagents, phosphate buffer & WFI water.

Production opens with receipt and QC of trifluoroacetylpteroic acid, the protected tyrosinate linker, and the S0456 dye. Pteroic acid is first coupled to the tyrosinate linker under amide-bond conditions using standard peptide coupling reagents in DMF. Removing the trifluoroacetyl group gives the folate-tyrosinate intermediate with a free phenoxy nucleophile. That intermediate is then combined with the S0456 dye under basic conditions, where the tyrosinate phenoxy displaces the meso-chloro on the dye and forms the phenoxyvinyl ether linkage that defines pafolacianine.

Crude pafolacianine is captured on preparative RP-HPLC, polished by a second orthogonal HPLC, and exchanged to the tetrasodium salt form. The solution is ultrafiltered, sterile-filtered through 0.22 micron membranes, and aseptically filled into single-dose 3 mL vials under Grade A air. QC covers assay, related pterin and dye impurities, residual solvents, endotoxin, fluorescence spectra, and container closure integrity. The main levers on cost are S0456 dye quality, coupling yield, HPLC recovery, and fluorescence purity.

Main Factors Affecting Pafolacianine Production Cost

Pafolacianine production cost is shaped mainly by its specialty inputs, and the S0456 heptamethine cyanine dye dominates the raw material line. It is a custom dye with a small number of qualified suppliers, and its price follows specialty cyanine chemistry. Trifluoroacetylpteroic acid is the next major cost, drawn from fine chemical houses that specialize in folate chemistry, and the protected tyrosinate linker and coupling reagents such as HBTU or HATU are smaller variable costs that still need GMP quality. DMF and DCM volume adds measurable cost, though recovery on the HPLC feed streams offsets some of it. Preparative RP-HPLC media is a real replacement cost at the low batch volumes typical for a niche injectable, and WFI water for the aseptic fill is a heavy utility item. On the testing side, RP-HPLC for related impurities, UV-Vis and fluorescence spectrometry, ICP-MS for residual palladium, and LAL for endotoxin make up most of the spend.

Unit cost also moves with the specialty cyanine-dye market, and any tightness in S0456 supply lengthens lead time and raises price. The shift toward larger clinical-supply lots for lung-cancer approvals has pushed HPLC and fill-line use higher, and reactor and column on-stream time weighs heavily on unit cost. The cleanroom, HPLC skid, and vial-fill line all carry heavy fixed overhead, so a plant running below capacity spreads that overhead over fewer grams and lands at a higher unit cost. Qualifying supply for hospital pharmacy formularies is a further slow step, taking months of clinical and pricing work.

Raw Materials for Pafolacianine Production Plant and its Procurement

Raw material sourcing for pafolacianine centers on a few specialty inputs. The S0456 heptamethine cyanine dye is the primary specialty feedstock, a meso-chloro-substituted, indocyanine-green-related dye from a narrow set of specialty suppliers, and its price reflects the multi-step cyanine synthesis behind it. Trifluoroacetylpteroic acid comes from folate-chemistry suppliers in India, China, and Europe, while the protected tyrosinate linker ships from custom peptide-chemistry houses. Coupling reagents such as HBTU, HATU, and DIC come from bulk fine chemical suppliers, and DMF, DCM, and buffer salts arrive in bulk. Water for injection completes the utility streams.

The cheapest S0456 is not always the cheapest route to finished API. A dye lot with elevated cyanine impurities raises related-substance carryover and shrinks HPLC yield, so the initial saving is lost in rework. Pteroic acid quality matters too, since related pterin isomers land in the API, and the linker's enantiomeric and regiochemical purity has to be controlled. Taken together, S0456 quality, pteroic acid assay, linker purity, DMF water content, and HPLC recovery account for most of the variable cost per gram.

These sensitivities shape how the plant buys and qualifies its inputs. Contracts specify dye assay, related cyanine impurities, water content, pteroic acid isomer limits, and endotoxin, and every incoming lot is quarantined until QC release. Vendor qualification for a GMP injectable plant includes on-site audits, review of dye batch records, and lot-to-lot monitoring, and long-term agreements with two qualified S0456 suppliers help steady both cost and timing. Siting the plant near a specialty peptide and dye cluster in Indiana, the US Northeast, India, or Europe adds a genuine freight and compliance advantage.

Sustainability and Regulatory Requirements

Pafolacianine manufacture raises environmental and occupational concerns that center on DMF and DCM use, deprotection-reagent handling, and cyanine dye waste. Standard controls rely on closed handling systems, activated-carbon vent scrubbers, DMF recovery loops, and incineration of dye-bearing waste. Wastewater carries amide solvents, spent buffer salts, TFA residues, and trace cyanine dye. Because cyanine dyes are lightfast to the eye but photosensitive on scale-up, light-protected process lines add a real operating cost. Work on lower-DMF conjugation solvents is under study.

Regulatory obligations follow from the API's use in an approved injectable imaging agent. In the US, pafolacianine falls under FDA cGMP oversight per 21 CFR 210/211, with the Cytalux label handled by CDER's imaging division, while the paired NIR imaging system is regulated separately by CDRH. ICH Q3A, Q3C, and Q3D apply, and aseptic manufacture runs under EU GMP Annex 1-equivalent controls. Sites typically carry ISO 14001 and ISO 45001 certification. No USP or EP monograph exists yet, since the molecule is still under patent.

CAPEX and OPEX for a Pafolacianine Production Plant

A pafolacianine plant needs a synthesis and purification train plus a sterile fill line. It starts with cyanine-dye cold-chain storage, a jacketed amide coupling reactor, a deprotection vessel, and a meso-chloro conjugation reactor with pH and temperature control. From there, a preparative RP-HPLC skid with two orthogonal columns, ultrafiltration and desalting, salt-form exchange to the tetrasodium salt, and sterile 0.22 micron filtration feed an aseptic small-volume vial-fill line under Grade A air. Utilities cover clean steam, purified water, WFI water, chilled brine, HEPA-filtered cleanroom air, nitrogen, and a thermal oxidizer for DMF and DCM vents, and a light-protected process aisle covers the cyanine-sensitive steps where required. A laboratory block typically houses RP-HPLC, UV-Vis, fluorescence spectrometry, LC-MS, LAL for endotoxin, and container-closure integrity testing, while civil works provide cGMP cleanroom bays, aseptic corridors, gowning, and a controlled-access API warehouse.

Pafolacianine operating cost is set by the same materials and control points that shape the process. The variable side is dominated by the S0456 dye, pteroic acid, the tyrosinate linker, and coupling reagents, alongside DMF, DCM, deprotection reagents, WFI water, labor, testing, wastewater treatment, packaging, and cold-chain freight. Cost per gram then turns on coupling yield, meso-chloro displacement efficiency, and HPLC recovery. Plant economics vary mainly with capacity, whether the site runs API only or adds aseptic fill, HPLC train size, and cleanroom class. Taken together, S0456 dye price, coupling efficiency, HPLC recovery, DMF recovery, and aseptic-fill overhead determine the running cost.

Plant Location and Investment Factors

A workable pafolacianine site sits inside a pharmaceutical cluster that supplies specialty dye, folate-chemistry vendors, GMP coupling reagents, and aseptic-fill contractors. A trained cGMP small-molecule injectable workforce is essential. West Lafayette in Indiana is the historic home of the folate-conjugate chemistry that led to OTL38, and On Target Laboratories runs its commercial program from Indiana; the US Northeast, North Carolina's Research Triangle Park, and Boulder, Colorado add to the specialty small-molecule injectable base. Indian clusters in Hyderabad and Ahmedabad and European sites in Switzerland and Italy would suit a future generic entrant. The site also needs GMP-grade wastewater treatment for the DMF and dye-bearing streams.

The main investment decision for a pafolacianine plant is whether to produce API only or to integrate aseptic fill-finish. An API-only plant is cheaper to build but adds cost and risk in cold-chain shipment, whereas on-site fill raises CAPEX yet secures supply integrity for a low-volume vial format. Backward integration into S0456 dye synthesis is a strategic question in its own right. Scale has to match a narrow addressable surgical case volume, and qualifying supply to hospital pharmacies is slow because Cytalux depends on a paired NIR imaging kit being in the operating room. For now, captive supply to On Target Laboratories is the decisive factor.

Major Pafolacianine Producing Regions

The US is the sole commercial production region for pafolacianine today. On Target Laboratories runs the Cytalux program from West Lafayette in Indiana, with API and aseptic fill-finish handled through qualified CDMO partners. Europe has no active production, though several EU CDMOs run compatible cyanine-dye capacity that could be qualified for future ex-US supply. Reference-standard grade is finished by catalog suppliers in the US, Europe, and China; bulk API is made at CDMO scale in the US, while research-grade lots run on smaller lines at the catalog houses. A future ex-US launch would most likely start in an EU aseptic-fill hub in Germany, Italy, or Ireland.

Key Pafolacianine Producers

On Target Laboratories, Inc.

• Developed OTL38 and holds worldwide commercial rights, with the Cytalux brand approved by the FDA for intraoperative identification of ovarian and lung cancer lesions.
• Runs the commercial program from West Lafayette in Indiana through qualified CDMO partners for API and aseptic vial fill-finish.
• Its cost position rests on tight control of the meso-chloro conjugation step, secured S0456 dye supply & captive CDMO relationships.
• Regulatory record covers FDA approvals in ovarian and lung cancer, active INDs in prostate and other folate-receptor-positive tumors & full cGMP compliance.

Selleckchem

• Distributes reference-standard pafolacianine and its S0456 dye component in milligram quantities for folate-receptor research & cyanine-dye assay work.
• Ships from Houston, with warehousing in China, Europe & Japan for rapid delivery to research customers.
• Competes on catalog breadth, next-day shipment & full analytical characterization with UV-Vis, HPLC & LC-MS data packs.
• Quality work covers assay above 98%, dye identity confirmation & lot-specific certificates for regulatory & publication use.

MedKoo Biosciences

• Supplies reference-standard pafolacianine for preclinical folate-receptor & NIR imaging research from its US base.
• Sources from qualified fine chemical partners and runs in-house QC under ISO 9001 process controls.
• Competes on cGMP-adjacent documentation, custom synthesis for larger research quantities & fast quotation.
• Quality controls cover HPLC assay, related substances, fluorescence check & lot-specific certificate of analysis.

BOC Sciences

• Provides pafolacianine and custom-synthesis services from its New York operations and China production base.
• Serves academic & industrial R&D customers, with scale-up to gram lots on request.
• Competes on cyanine chemistry expertise, custom-lot flexibility & bundled analytical services.
• Quality documentation covers HPLC assay, fluorescence spectrum, residual solvents & elemental impurities.

Cayman Chemical

• Distributes S0456 dye & pafolacianine reference material to academic and industrial research groups from Ann Arbor.
• Ships directly to research accounts and through third-party distributors in Europe & Asia.
• Competes on dye catalog depth, technical support & documented characterization for niche imaging-agent research.
• Quality documentation covers HPLC assay, UV-Vis absorbance, fluorescence emission & lot-specific data packs.

AmbioPharm Inc.

• Produces GMP pafolacianine-class conjugate APIs from its North Augusta, South Carolina site and its China facility.
• Sources amino acid, linker & cyanine dye captively through partnerships in Asia, Europe & North America.
• Competes on peptide-conjugate manufacturing scale, price against top-tier CDMOs & the ability to serve early- and late-stage sponsors.
• Regulatory work covers FDA cGMP inspection, ISO 9001 & ICH Q7 compliance with full CMC documentation.